 Once patient eligibility is confirmed and the screening procedures completed, the patient will start the Treatment Period of the study. All enrolled patients will receive either 5 SAN007 cream or placebo cream randomized in a 2:1 ratio with the first dose applied at the Day 1 Study Visit. Patients andor their legally authorized representative will be instructed on how to apply the study medication twice daily for 28 days. Patients will return to the clinic on Study Days 7,14 and 28 for study-related assessments. Patients andor their LAR will receive a telephone contact from the site, on Study Days 21 and 35. 